Exicure, Inc. (XCUR) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exicure, Inc. on December 30, 2021, with a report date of January 5, 2022. The filing addresses the termination of a material definitive agreement, preliminary financial condition as of December 31, 2021, a notice of failure to satisfy Nasdaq listing standards, and updates regarding the company's strategic wind-down of specific clinical programs.
Key Financial Metrics
The filing provides preliminary, unaudited estimates for the period ended December 31, 2021. The company does not provide revenue, profit, or cash flow data in this filing.
- Cash Position: Approximately $48.3 million in cash, cash equivalents, and restricted cash.
- Debt: Principal amount of outstanding debt estimated at $7.5 million.
- Capital Structure:
- Common Stock Outstanding: 108,783,144 shares.
- Warrants Outstanding: 17,288,034 shares at an exercise price of $0.2701.
- Pre-funded Warrants Outstanding: 14,000,000 shares at an exercise price of $0.001.
Material Changes and Events
- Termination of Sales Agreement: The equity distribution agreement ("Sales Agreement") with BMO Capital Markets Corp., which allowed for an "at-the-market" offering of up to $50.0 million, was terminated effective January 4, 2022. No further shares will be sold under this agreement.
- Nasdaq Delisting Notice: The company received notice from Nasdaq that its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days. The company has an initial 180-day compliance period (until June 28, 2022) to regain compliance.
- Program Wind-Down: The company is proceeding with a plan to wind down its immuno-oncology program for cavrotolimod (AST-008) while seeking strategic collaborations to maximize value.
Outlook, Risks, and Management Commentary
Management intends to monitor the stock bid price and consider options, including a potential reverse stock split, to achieve compliance with Nasdaq listing rules. The company is updating its corporate presentation to reflect its revised business strategy and cash position. Significant risks include the potential for delisting if compliance is not met, the uncertainty of the wind-down process for the cavrotolimod program, and the possibility that actual financial results may differ from the preliminary estimates provided due to ongoing audit procedures.
Investor Verification Checklist
- Verify the final audited cash balance and debt principal for the year ended December 31, 2021, as the figures in this filing are preliminary estimates.
- Monitor the daily closing bid price of XCUR stock to assess progress toward the $1.00 Nasdaq compliance threshold.
- Review the attached corporate presentation (Exhibit 99.1) for detailed updates on the revised business strategy and cost-saving measures.
- Confirm the status of the cavrotolimod (AST-008) program wind-down and any potential strategic partnership announcements.
- Check for future filings regarding the outcome of the Nasdaq compliance period or any appeal of a potential delisting determination.